 |
A methodology for the analysis of PSA response signatures |
Ebert, Martin A.; Lamb, David S.; Joseph, David J.; Steigler, Allison; Denham, James W. |
2011 |
—
|
|
 |
Measuring time to biochemical failure in the Trog 96.01 trial: when should the clock start ticking? |
Denham, James W.; Steigler, Allison; Gleeson, Paul S.; D'Este, Catherine; Kumar, Mahesh... More
|
2009 |
—
|
|
 |
PSA response signatures: a powerful new prognostic indicator after radiation for prostate cancer? |
Denham, James W.; Lamb, David S.; Joseph, David; Matthews, John; Atkinson, Chris... More
|
2009 |
—
|
|
 |
A randomized controlled trial of an exercise intervention targeting cardiovascular and metabolic risk factors for prostate cancer patients from the RADAR trial |
Galvão, Daniel A.; Spry, Nigel; Taaffe, Dennis R.; Denham, James; Joseph, David... More
|
2009 |
|
|
 |
Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer |
Denham, James W.; Kumar, Mahesh; Turner, Sandra; Greer, Peter B.; D'Este, Catherine... More
|
2009 |
—
|
|
 |
Survival benefit confirmed for prostate cancers diagnosed by PSA testing (letter) |
Lamb, David S.; Delahunt, Brett; Denham, James; Slaney, David |
2009 |
—
|
|
 |
Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival? |
Denham, James W.; Steigler, Allison; Wilcox, Chantelle; Lamb, David S.; Joseph, David... More
|
2009 |
—
|
|
 |
Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial |
Denham, James W.; Steigler, Allison; Gleeson, Paul S.; Greer, Peter B.; D'Este, Catherine... More
|
2008 |
—
|
|
List View
